SPTX (Seaport Therapeutics) ROIC %: -415.64% (As of Dec. 2025)


SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $21.43
! 1 Warning Sign
View Full Analysis

What is Seaport Therapeutics ROIC %?

Seaport Therapeutics SPTX +10.37% 11 ROIC % is -415.64% as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Seaport Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was -415.64%.

As of today (2026-06-27), Seaport Therapeutics's WACC % is 10.33%. Seaport Therapeutics's ROIC % is -415.64% (calculated using TTM income statement data). Seaport Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Seaport Therapeutics  (NAS:SPTX) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Seaport Therapeutics's WACC % is 10.33%. Seaport Therapeutics's ROIC % is -415.64% (calculated using TTM income statement data). Seaport Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Seaport Therapeutics ROIC % Related Terms


Seaport Therapeutics ROIC % Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics ROIC % Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
ROIC %
-557.80 -415.64

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
ROIC % -557.80 -415.64

SPTX vs LXRX, DRTS, MGTX: ROIC % Comparison

For the Biotechnology subindustry, Seaport Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seaport Therapeutics ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seaport Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Seaport Therapeutics's ROIC % falls into.


SPTX
11GF Score
Seaport Therapeutics Inc SPTX
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics ROIC % Calculation

Seaport Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-87.294 * ( 1 - 0% )/( (9.397 + 32.608)/ 2 )
=-87.294/21.0025
=-415.64 %

where

Seaport Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-87.294 * ( 1 - 0% )/( (9.397 + 32.608)/ 2 )
=-87.294/21.0025
=-415.64 %

where

Note: The Operating Income data used here is one times the annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -415.64% mean?
Seaport Therapeutics (SPTX) has a ROIC % of -415.64% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Seaport Therapeutics and its competitors.
Is Seaport Therapeutics' ROIC % too high?
Seaport Therapeutics' current ROIC % is -415.64%. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' ROIC % compare to LXRX and DRTS?
Seaport Therapeutics' ROIC % of -415.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Seaport Therapeutics and its competitors. Seaport Therapeutics's current ROIC % is -415.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current ROIC % of -415.64%. The current ROIC % is -415.64%. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current ROIC % is -415.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.43
Price